The antibody MEM-83 reacts with an extracellular epitope of CD11a (alpha subunit of human LFA-1), a 170-180 kDa type I transmembrane glycoprotein expressed on B and T lymphocytes, monocytes, macrophages, neutrophils, basophils and eosinophils.
ITGAL
Reaktivität: Human
FACS, IP
Wirt: Maus
Monoclonal
MEM-25
Biotin
Applikationshinweise
Functional application: The antibody MEM-83 directly induces the binding of T cells to purified ICAM-1. Using an in vitro-translated CDlla cDNA deletion series, the MEM-83 activation epitope was mapped to the "I" domain of the LFA-1 alpha subunit. The studies have therefore identified a novel LFA-1 activation epitope mapping to the I domain of LFA-1, which could play a role in the regulation of LFA-1 binding to ICAM-1. Flow cytometry: Recommended dilution: 1 μg/mL.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Konzentration
1 mg/mL
Buffer
Phosphate buffered saline (PBS), pH 7.4
Konservierungsmittel
Azide free
Handhabung
Do not freeze.
Lagerung
4 °C
Informationen zur Lagerung
Store at 2-8°C. Do not freeze.
Landis, McDowall, Holness, Littler, Simmons, Hogg: "Involvement of the "I" domain of LFA-1 in selective binding to ligands ICAM-1 and ICAM-3." in: The Journal of cell biology, Vol. 126, Issue 2, pp. 529-37, (1994) (PubMed).
Landis, Bennett, Hogg: "A novel LFA-1 activation epitope maps to the I domain." in: The Journal of cell biology, Vol. 120, Issue 6, pp. 1519-27, (1993) (PubMed).
Integrin subunit alpha L,CD11a (LFA-1 alpha) together with CD18 constitute leukocyte function-associated antigen 1 (LFA-1), the alphaLbeta2 integrin. CD11a is implicated in activation of LFA-1 complex. LFA-1 is expressed on the plasma membrane of leukocytes in a low-affinity conformation. Cell stimulation by chemokines or other signals leads to induction the high-affinity conformation, which supports tight binding of LFA-1 to its ligands, the intercellular adhesion molecules ICAM-1, -2, -3. LFA-1 is thus involved in interaction of various immune cells and in their tissue-specific settlement, but participates also in control of cell differentiation and proliferation and of T-cell effector functions. Blocking of LFA-1 function by specific antibodies or small molecules has become an important therapeutic approach in treatment of multiple inflammatory diseases. For example, humanized anti-LFA-1 antibody Efalizumab (Raptiva) is being used to interfere with T cell migration to sites of inflammation, binding of cholesterol-lowering drug simvastatin to CD11a allosteric site leads to immunomodulation and increase in lymphocytic cholinergic activity.,LFA-1, LFA1A, ITGAL